Abstract
PTPN11 encodes the SHP2 protein tyrosine phosphatase which regulates cell survival and proliferation primarily by activating the RAS-MAPK signaling pathway. Abnormal expression or activation of SHP2 is associated with various tumorigenesis, such as lung cancer. Thus, targeting SHP2 has emerged as a promising oncology therapy. Several SHP2 allosteric inhibitors, such as ICP-189 and RMC-4630, have been entered into clinical trials. However, the mutational landscape of PTPN11 remains unclear, we systematically analyzed the genomic profiling of PTPN11 in Chinese lung cancer patients (pts).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
